AlveoGene

Innovative gene therapy company created by Oxford Science Enterprises (OSE), Harrington Discovery Institute at University Hospitals (Harrington), and Old College Capital (OCC), the University of Edinburgh’s venture investment fund, in partnership with six leading scientists from the world-renowned UK Respiratory Gene Therapy Consortium (GTC).

Branding, corporate livery, website design and build

Having worked with Founder and Executive Chair David Hipkiss on a previous company’s rebrand, it was a pleasure to be asked by him to prepare the launch of new venture AlveoGene. Working closely with David we developed a compelling and unified brand identity across logo, style guide, investor deck and website. The result was striking, modern, appealing to both the investment and scientific communities and visually resonant at all times of the innovative gene therapy at the heart of the company.

Forty6 Design were simply brilliant and very effective in both time and cost for AlveoGene. In short order they were able to take a complex modality and therapeutic concept and transform it into a modern and highly impactful visual identity that allows for both significant differentiation and instant recognition. The concept has seamlessly transitioned across all media including website, letterhead, presentation templates and business cards. I have been particularly impressed that our on-line presence works independent of platform, device or operating system, which allows for faultless global interaction from clients and investors alike. I could not recommend them more highly.

David Hipkiss, founder and executive chair

AlveoGene

Other projects

aVaxziPen

aVaxziPen

Cambridge Consultants

Cambridge Consultants

Circle Health Group

Circle Health Group

Enesi Pharma

Enesi Pharma

Immodulon Therapeutics

Immodulon Therapeutics

Kesmalea

Kesmalea

Molecure

Molecure

New Model Medicine

New Model Medicine

New Science Ventures

New Science Ventures

Pneumagen

Pneumagen

Looking to attract investors?